SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Longeveron’s Laromestrocel Shows Fewer Major Adverse Cardiac Events in Phase 2b Trial

LGVN

Story updates

01:28:23 PM UTC
SquawkNews
BRIEF-Longeveron Announces Updated Results From Elpis Ii Phase 2B Clinical Trial Evaluating Laromest

Related stories